Quest Diagnostics Incorporated (DGX)

Quest Diagnostics' stock (DGX) has experienced an increase of 21.09% over the past year, as of April 7, 2025, to April 6, 2026, with a 52-week trading range between $160.02 and $213.50. In July 2025, Quest Diagnostics raised its 2025 profit and revenue forecasts due to robust demand for its diagnostic tests, leading to a more than 3% rise in its shares in premarket trading. More recent news mentioned a target cut by Evercore and the company being down 4.2% since its last earnings report.

Demand for Quest Diagnostics' products and services appears to be relatively stable, with steady demand for diagnostic checkups driven by factors such as non-urgent surgeries, particularly among older Americans. The company has also benefited from agreements to manage hospital laboratories, contributing to its market share expansion. While the provided information indicates consistent demand, specific seasonal peaks or troughs in demand for its various testing services are not explicitly detailed.

Quest Diagnostics, Inc. (DGX) is a leading American clinical laboratory and a Fortune 500 company in the healthcare sector, specifically within the Diagnostics & Research industry. The company provides diagnostic testing and information services, including routine, non-routine, and advanced clinical testing, anatomic pathology, esoteric testing, and substance abuse testing. Quest Diagnostics also offers clinical trials testing, risk-assessment services, and healthcare information technology solutions and is at the forefront of advanced gene-based and molecular testing, wellness, and population health solutions.

Quest Diagnostics is headquartered in Secaucus, New Jersey, USA, and has a significant international presence with operations in India, Ireland, Mexico, and Brazil. Its products and services are utilized by customers across more than 130 countries and on six continents. In the United States, Quest Diagnostics has a national network of laboratories in most major metropolitan areas and approximately 2,000 patient service centers. Globally, it collaborates with numerous international diagnostic laboratories, hospitals, and clinics.

Quest Diagnostics has consistently maintained a strong brand reputation and has been recognized by FORTUNE magazine as one of the "World's Most Admired Companies" for multiple consecutive years, including its eighth consecutive appearance in 2022, ninth in 2023, tenth in 2024, and twelfth in 2026. Additionally, Quest Diagnostics has been acknowledged on other influential lists for its work in areas like inclusion & diversity, environmental sustainability, and as one of America's Most Trustworthy Companies and America's Greatest Workplaces.

The ownership of Quest Diagnostics, Inc. (DGX) is predominantly held by institutional investors, including The Vanguard Group, Inc., BlackRock, Inc., T. Rowe Price Group, Inc., and State Street Global Advisors, Inc. These institutions collectively hold a substantial number of shares, with 1038 institutional owners holding a total of 104,794,457 shares. Institutional investors hold approximately 78.27% or 49.41% of the company's stock, while retail investors and insiders hold smaller percentages.